Intimation of re-appointment of Internal Auditor.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's Board of Directors has approved the re-appointment of M/s. Ernst & Young LLP (EY) as the company's Internal Auditors for another one-year term from June 2026 to May 2027. This is a routine annual re-appointment as part of standard corporate governance practices. The decision was made at the Board meeting held on May 21, 2026, which lasted from 4:30 p.m. to 6:25 p.m. EY is a globally recognized auditing firm that provides risk assessment, process improvement, technology integration, and regulatory compliance services to the company. The filing was made pursuant to Regulation 30 of the SEBI Listing Regulations.
This is a routine corporate governance matter with no material impact on shareholders or stock price. The continuity of a reputable auditor like EY indicates normal operations and good internal control practices.